Wolf Theiss

DEVELOPING TREATMENTS FOR COVID-19: CONDITIONAL MARKETING AUTHORIZATION, COMPASSIONATE USE, AND NAMED PATIENT SUPPLY

In view of the current endeavours to develop vaccines or medicines against Covid-19, this pandemic raises the question of when these products will be available for fighting the disease. More specifically: Will these products have to go through the same lengthy marketing authorization procedures as do other medicinal products, or are there any faster ways to bring these products to use? In order to find out more, please download the file below.

For further information please contact

Georg Kresbach
Georg
Kresbach
Partner
Austria
Maren Jergolla-Wagner
Maren
Jergolla-Wagner
Senior Associate
Austria

Find a Lawyer

Top